Real-world outcomes of immune checkpoint inhibitors as second-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective analysis
In this study, 2L-ICIs demonstrate significant clinical benefits with acceptable toxicity in ES-SCLC patients who progressed after 1L therapy, supporting their use as a clinically actionable option.
Authors
- Xiao-ye Jin
- Lujun Zhao (ORCID: https://orcid.org/0000-0001-5960-0201)
- Yan Wang
- Ping Li (ORCID: https://orcid.org/0000-0002-8515-7773)
- Jiao Zhang (ORCID: https://orcid.org/0000-0002-2219-944X)
- Jiaxing Guo
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
- Inner Mongolia Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1658017
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00